Alnylam Commits Up to $2B to AI-Driven Therapeutic Innovation -- Company Talk

Dow Jones

06/04

Alnylam's new strategic partnership with Inceptive Nucleics carries a potential value of up to $2 billion, with an upfront payment of $30 million in cash and equity. The deal pairs Inceptive's generative artificial intelligence models with Alnylam's research engine as part of the company's Alnylam 2030 strategy. Alnylam CEO Yvonne Greenstreet said the collaboration aims to accelerate the creation of transformative medicines with speed and sophistication not previously possible. The structure includes additional milestone payments tied to preclinical, regulatory, and commercial achievements.

This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.

(END) Dow Jones Newswires

June 03, 2026 17:28 ET (21:28 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2640182669"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2640182669\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2640182669?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-04 05:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640182669","market":"nz","top_or_hot":-1,"title":"Alnylam Commits Up to $2B to AI-Driven Therapeutic Innovation -- Company Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Alnylam's new strategic partnership with Inceptive Nucleics carries a potential value of up to $2 billion, with an upfront payment of $30 million in cash and equity. The deal pairs Inceptive's generative artificial intelligence models with Alnylam's research engine as part of the company's Alnylam 2030 strategy. Alnylam CEO Yvonne Greenstreet said the collaboration aims to accelerate the creation of transformative medicines with speed and sophistication not previously possible. The structure includes additional milestone payments tied to preclinical, regulatory, and commercial achievements. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n     This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 03, 2026 17:28 ET (21:28 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alnylam Commits Up to $2B to AI-Driven Therapeutic Innovation -- Company Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlnylam Commits Up to $2B to AI-Driven Therapeutic Innovation -- Company Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-06-04 05:28</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  Alnylam's new strategic partnership with Inceptive Nucleics carries a potential value of up to $2 billion, with an upfront payment of $30 million in cash and equity. The deal pairs Inceptive's generative artificial intelligence models with Alnylam's research engine as part of the company's Alnylam 2030 strategy. Alnylam CEO Yvonne Greenstreet said the collaboration aims to accelerate the creation of transformative medicines with speed and sophistication not previously possible. The structure includes additional milestone payments tied to preclinical, regulatory, and commercial achievements. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n     This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 03, 2026 17:28 ET (21:28 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0109394709.USD","symbol_name":"富蘭克林生物科技新領域基金A (acc)","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2640182669","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640182669","pubTimestamp":1780522080,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Alnylam's new strategic partnership with Inceptive Nucleics carries a potential value of up to $2 billion, with an upfront payment of $30 million in cash and equity. The deal pairs Inceptive's generative artificial intelligence models with Alnylam's research engine as part of the company's Alnylam 2030 strategy. Alnylam CEO Yvonne Greenstreet said the collaboration aims to accelerate the creation of transformative medicines with speed and sophistication not previously possible. The structure includes additional milestone payments tied to preclinical, regulatory, and commercial achievements.This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","ARTY":"ISHARES FUTURE AI & TECH ETF","BK4548":"巴美列捷福持仓","BK4139":"生物科技","AGIX":"通用人工智能 ETF-AGIX","ALNY":"阿尔尼拉姆制药公司","AIPO":"Defiance AI and Power Infrastructure ETF","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","BK4585":"ETF&股票定投概念","BK4588":"碎股","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC"},"translate_title":"Alnylam承诺投入高达20亿美元用于人工智能驱动的治疗创新——公司演讲","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGIX":1.5,"ARTY":1.5,"AIPO":1.5,"CHAT":1.5,"ALNY":0.9},"content_text":"Alnylam's new strategic partnership with Inceptive Nucleics carries a potential value of up to $2 billion, with an upfront payment of $30 million in cash and equity. The deal pairs Inceptive's generative artificial intelligence models with Alnylam's research engine as part of the company's Alnylam 2030 strategy. Alnylam CEO Yvonne Greenstreet said the collaboration aims to accelerate the creation of transformative medicines with speed and sophistication not previously possible. The structure includes additional milestone payments tied to preclinical, regulatory, and commercial achievements. \n\n\n \n\n\n     This article was automatically created using artificial-intelligence technology and reviewed by Dow Jones Newswires editors. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 03, 2026 17:28 ET (21:28 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}